Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of AstraZeneca's Sipavibart?
Sipavibart is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Coronavirus Disease 2019 (COVID-19). According...